FDA rejected Moderna’s mRNA flu vaccine due to flawed trial design and comparator, raising concerns over regulatory consistency and innovation.

India and Brazil signed an agreement to cooperate on pharmaceutical regulations, aiming to improve safety, quality, and access to medical products.

A promising nasal spray vaccine in mice offers broad, long-lasting protection against flu, COVID-19, colds, pneumonia, and allergens with just one dose, potentially eliminating annual shots, but human trials are still needed.

Women experience longer pain after injury due to biological differences in immune cells, a study finds.

Johnson & Johnson invests $1B in Pennsylvania to build a cell therapy plant, creating 4,500 jobs, part of a broader U.S. push for domestic advanced medicine manufacturing.

Cats and humans share key cancer genes, with study revealing similar tumor mutations and treatment responses, advancing precision medicine for both.

A new blood test may predict Alzheimer’s onset within 3–4 years, but isn’t yet reliable for healthy people.

FDA to shift from two to one clinical trial for most new drug approvals to accelerate access.

A Tetris-like game played after recalling trauma cuts flashbacks by 90%, offering a simple, scalable PTSD tool.

Gilead acquires Arcellx for $7.8B to gain control of anito-cel, a CAR T-cell therapy for multiple myeloma, with FDA decision expected by Dec. 23, 2026.